Fewer than a tenth of individuals who could benefit from obesity jabs including Wegovy have access to them, states the World Health Organization as it releases its initial recommendations on the therapies.
Considering in excess of 1,000,000,000 people worldwide now obese, it is calling for increased and just access to these injectable treatments.
Based on projections, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"The new guidelines recognises that excess weight is a lifelong illness that can be addressed with thorough and continuous support," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and logistical bottlenecks are significant barriers to universal access to the treatments that can assist patients in reducing significant weight, says the body.
GLP-1 Therapy Scarcity
Despite the present best projected case, the production of such drugs could only cover approximately 100 million people – under 10% of the global need, as stated by the WHO.
The guideline urges nations and manufacturers to increase access, via approaches like voluntary licensing.
Exclusive production rights on semaglutide – the main component of Novo Nordisk's Wegovy – is due to expire in a number of nations in 2026.
How Weight-Loss Jabs Operate
GLP-1 drugs mimick a biological compound to slow digestion, curb appetite and increase the sense of being full so users consume fewer calories.
People usually see weight reduction within a few weeks of beginning the weekly injections.
Studies suggests people may put most of the weight back on within a year of discontinuing the medication, because their normal hunger resume.
Being above a healthy weight increases your risk for contracting health problems, such as diabetes, cardiovascular issues, brain attack, and specific cancers.
Obesity concerns people in countries worldwide and was associated with over three and a half million deaths worldwide in 2024, according to the health agency.
